Analysts Set Merus (NASDAQ:MRUS) PT at $85.45

Merus (NASDAQ:MRUS) has been given an average rating of “Buy” by the fourteen analysts that are presently covering the stock, Marketbeat reports. Twelve analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $85.27.

MRUS has been the topic of several recent analyst reports. HC Wainwright reissued a “buy” rating and set a $85.00 target price on shares of Merus in a report on Monday, December 2nd. The Goldman Sachs Group assumed coverage on Merus in a report on Thursday, November 21st. They issued a “buy” rating and a $73.00 price objective for the company. Guggenheim reaffirmed a “buy” rating and set a $109.00 target price (down from $111.00) on shares of Merus in a report on Tuesday, December 3rd. Needham & Company LLC reissued a “buy” rating and issued a $85.00 price target on shares of Merus in a report on Monday, December 2nd. Finally, UBS Group initiated coverage on shares of Merus in a research note on Thursday, October 24th. They issued a “buy” rating and a $72.00 price objective on the stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. nVerses Capital LLC raised its holdings in shares of Merus by 750.0% during the third quarter. nVerses Capital LLC now owns 1,700 shares of the biotechnology company’s stock valued at $85,000 after acquiring an additional 1,500 shares during the period. US Bancorp DE purchased a new position in Merus during the 3rd quarter worth approximately $103,000. Mirae Asset Global Investments Co. Ltd. raised its stake in Merus by 24.7% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,467 shares of the biotechnology company’s stock valued at $118,000 after purchasing an additional 489 shares during the period. MML Investors Services LLC purchased a new stake in shares of Merus in the third quarter valued at $206,000. Finally, Farallon Capital Management LLC acquired a new stake in shares of Merus in the second quarter worth $237,000. 96.14% of the stock is currently owned by institutional investors and hedge funds.

Merus Trading Up 1.8 %

Shares of Merus stock opened at $44.65 on Tuesday. The stock has a market capitalization of $3.06 billion, a price-to-earnings ratio of -11.30 and a beta of 1.07. Merus has a twelve month low of $22.27 and a twelve month high of $61.61. The business’s 50 day simple moving average is $49.73 and its 200-day simple moving average is $51.86.

Merus (NASDAQ:MRUS) last released its quarterly earnings results on Thursday, October 31st. The biotechnology company reported ($0.95) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.90) by ($0.05). The business had revenue of $11.77 million during the quarter, compared to the consensus estimate of $9.11 million. Merus had a negative return on equity of 38.89% and a negative net margin of 680.61%. Sell-side analysts predict that Merus will post -3.89 earnings per share for the current year.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.